中国重度抑郁症患者中PDLIM5基因多态性与短期抗抑郁反应
PDLIM5 gene polymorphisms and short term antidepressant response in Chinese major depressive disorders.
作者信息
Liu Zhongchun, Zhu Fan, Yao Lihua, Yang Can, Xiao Ling, Zhu Junhong, Wang Huiling, Wang Gaohua, Liu Wanhong, Xiao Zheman
机构信息
Department of Psychiatry, Renmin Hospital, Wuhan University Wuhan, China ; Institute of Neuropsychiatry, Renmin Hospital, Wuhan University Wuhan, China.
出版信息
Int J Clin Exp Med. 2013 Sep 1;6(8):677-82. eCollection 2013.
Several investigations have suggested that PDLIM5 plays a key role in the pathophysiology of major depressive disorder (MDD), and that PDLIM5 might be a therapeutic target for the action of antidepressant. In this study, we sought to investigate whether variations of PDLIM5 gene sequence could predict response to antidepressants in MDD patients. We selected 3 SNPs (rs10008257, rs2433320, 2452600) of PDLIM5 gene, and performed an association analysis of PDLIM5 and the efficacy of fluoxetine treatment in 185 Han Chinese MDD patients. The results show that the rs2433320 of PDLIM5 gene are associated with fluoxetine therapeutic response in MDD patients (X(2) = 8.2960, df = 2, P = 0.0145) after correction with the Bonferroni multiple test, the HAMD score of the GG genotype group was significantly lower than that of the AA and AG genotype group at 1, 2, 4 and 6 weeks. The results support the idea that the PDLIM5 gene is likely to be involved in the antidepressant response in MDD.
多项研究表明，PDLIM5在重度抑郁症（MDD）的病理生理学中起关键作用，并且PDLIM5可能是抗抑郁药作用的治疗靶点。在本研究中，我们试图调查PDLIM5基因序列的变异是否可以预测MDD患者对抗抑郁药的反应。我们选择了PDLIM5基因的3个单核苷酸多态性（SNP，rs10008257、rs2433320、2452600），并对185例汉族MDD患者进行了PDLIM5与氟西汀治疗疗效的关联分析。结果显示，经Bonferroni多重检验校正后，PDLIM5基因的rs2433320与MDD患者的氟西汀治疗反应相关（X(2)=8.2960，自由度=2，P=0.0145），GG基因型组在1、2、4和6周时的汉密尔顿抑郁量表（HAMD）评分显著低于AA和AG基因型组。这些结果支持了PDLIM5基因可能参与MDD患者抗抑郁反应的观点。
Zotero 插件